Prognostic and Predictive Value of Baseline and Posttreatment Molecular Marker Expression in Locally Advanced Rectal Cancer Treated With Neoadjuvant Chemoradiotherapy

Bertolini, Federica; Bengala, Carmelo; Losi, Luisa; Pagano, Maria; Iachetta, Francesco; Dealis, Cristina; Jovic, Gordana; Depenni, Roberta; Zironi, S.; Falchi, A.; Luppi, Gabriele; Conte, Pierfranco

doi:10.1016/j.ijrobp.2007.02.018

Cited by 99 publications

(100 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Early small series with little clinical detail and much heterogeneity reported rates of pathologic response between 0 and 60% (Bertolini et al, 2007;Cecchin et al, 2011;Charara et al, 2004;Lim et al, 2015;Shin et al, 2013). However, in the largest series to date pathologic response was found to be excellent, with a complete pathologic response (pCR) of 27.6% in locally advanced disease (de Rosa et al, 2016) compared to a pCR rate of 18% among patients without LS treated with neoadjuvant chemoradiation (Park et al, 2012).…”

Section: Rectal Cancer With Msimentioning

confidence: 99%

The current value of determining the mismatch repair status of colorectal cancer: A rationale for routine testing

Ryan

Sheahan

Creavin

et al. 2017

Critical Reviews in Oncology/Hematology

118

View full text Add to dashboard Cite

Section: Rectal Cancer With Msimentioning

confidence: 99%

The current value of determining the mismatch repair status of colorectal cancer: A rationale for routine testing

Ryan

Sheahan

Creavin

et al. 2017

Critical Reviews in Oncology/Hematology

118

View full text Add to dashboard Cite

“…At present, the following drugs for the treatment of various forms of colorectal cancer have been registered by the Food and Drug Administration (FDA): fluorouracil capecitabine irinotecan, and oxaliplatin cetuximab bevacizumab [10][11][12]. Additionally, the following drug kits have been registered: -IFL (irinotecan, bolus fluorouracil + leucovorin) -first-line treatment of advanced colorectal cancer with distant metastases; -FOLFOX (oxaliplatin fluorouracil infused + leucovorin) -first-or second-line treatment of advanced colorectal cancer with distant metastases; -fluorouracil + bevacizumab -first-line treatment of advanced colorectal cancer with distant metastases; -cetuximab + irinotecan -second-line treatment of advanced colorectal cancer with distant metastases after detection of the presence of receptor for the epidermal growth factor (EGF).…”

Section: Chemotherapy Of Colorectal Cancermentioning

confidence: 99%

Contemporary methods of treatment of colorectal cancer

Kozłowska¹,

Głuszek²

2015

View full text Add to dashboard Cite

Today, colorectal cancer (CRC) is the third most frequently diagnosed worldwide malignant cancer in males, and the second in females, with more than 1,200,000 new cases and more than 600,000 deaths, annually. Screening tests in oncology allow the detection of cancerous disease at an early, asymptomatic stage. The procedures most frequently performed in the case of colorectal cancer include: low anterior resection by the Dixon method (manual suture or staplers); abdominoperineal resection of the rectum by the Miles method; surgical procedure by the Hartmann method; local resection. Various techniques of preoperative radiotherapy are applied, aimed at tumour mass reduction (scheme I) and/or obtaining local sterilisation (schemes I and II), which results in the reduction of local metastases (by approximately 50%), as well as an improvement with respect to long-term survival (by approximately 10%). At present, the following drugs for treatment of various forms of colorectal cancer have been registered by the Food and Drug Administration (FDA): fluorouracil capecitabine irinotecan, oxaliplatin, cetuximab, and bevacizumab. The combination of complete cytoreductive surgery (CCS), the goal of which is the removal of all visible (macroscopically) cancer foci, with a simultaneous intraperitoneal chemotherapy in hyperthermia -HIPEC, destroying microscopic remains of the disease, allows the curing of some patients with peritoneal cancer. The effect of the action of monoclonal antibodies -cetuximab and panitumumab -is the inhibition of proliferation of cancer cells, intensification of their apoptosis, as well as reduction of synthesis and secretion of pro-angiogenic factors, such as interleukin 8 (IL-8) and vascular endothelial growth factor. In addition, antibodies targeted against EGFR impair the repair of DNA damage caused by chemotherapy and radiotherapy in the cells of the malignant tumour. StreszczenieWspółcześnie rak jelita grubego jest trzecim najczęściej diagnozowanym nowotworem złośliwym na świecie u mężczyzn, a drugim u kobiet, z ponad 1 200 000 nowymi przypadkami i ponad 600 000 zgonami rocznie. Badania przesiewowe w onkologii pozwalają wykrywać chorobę nowotworową we wczesnej, bezobjawowej fazie. Do najczęściej wykonywanych zabiegów w przypadku raka odbytnicy należą: niska przednia resekcja sposobem Dixona (zespolenie ręczne lub staplery), amputacja brzuszno-kroczowa odbytnicy sposobem Milesa, operacja sposobem Hartmanna i wycięcie miejscowe. Stosuje się różne techniki radioterapii przedoperacyjnej, która ma na celu zmniejszenie masy guza (schemat I) i/lub uzyskanie sterylizacji miejscowej (schemat I, II), co wpływa na zmniejszenie wznów miejscowych (o ok. 50%) oraz poprawę przeżyć odległych (o ok. 10%). Obecnie do leczenia różnych postaci raka jelita grubego, w tym odbytnicy, zostały zarejestrowane przez Agencję ds. Żywności i Leków (FDA) następujące leki: fluorouracyl, kapecytabina, irinotekan, oksaliplatyna, cetuksymab, bewacizumab. Połączenie operacji całkowitej cytoredukcji, mającej na celu usunięci...

show abstract

“…TYMS is considered the indirect target of 5-fluorouracil (5-Fu) and it was evaluated in several studies as a predictor of response to 5-Fu based pre-CRT in LARC (71)(72)(73)(74)(75)(76), but there is much debate about the results. Saw et al (71) observed that pretreatment biopsy specimens negative for TYMS were predictive of tumor down-staging in the CRT group but not in the radiotherapy group.…”

Section: Thymidylate Synthase (Tyms)mentioning

confidence: 99%

Prediction of response to preoperative chemoradiotherapy in patients with locally advanced rectal cancer

Meng

Huang

Wang

et al. 2014

BST

View full text Add to dashboard Cite

Prognostic and Predictive Value of Baseline and Posttreatment Molecular Marker Expression in Locally Advanced Rectal Cancer Treated With Neoadjuvant Chemoradiotherapy

Cited by 99 publications

References 30 publications

The current value of determining the mismatch repair status of colorectal cancer: A rationale for routine testing

The current value of determining the mismatch repair status of colorectal cancer: A rationale for routine testing

Contemporary methods of treatment of colorectal cancer

Prediction of response to preoperative chemoradiotherapy in patients with locally advanced rectal cancer

Contact Info

Product

Resources

About